Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's first patented compound, CR665, has entered clinical testing for acute pain. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.